Aliases & Classifications for Lens Disease

Summaries for Lens Disease

MalaCards based summary : Lens Disease, also known as lens diseases, is related to cataract and isolated ectopia lentis, and has symptoms including eye manifestations An important gene associated with Lens Disease is CRYAA (Crystallin Alpha A). The drugs Norgestimate and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye and retina, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 The lens is a transparent, biconvex structure in the eye that, along with the cornea, helps to refract... more...

Related Diseases for Lens Disease

Diseases related to Lens Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 cataract 29.8 PITX3 PAX6 OCRL MYH9 GJA3 FOXE3
2 isolated ectopia lentis 10.8
3 traumatic glaucoma 10.3 PHEX OPTN
4 chronic closed-angle glaucoma 10.3 PHEX OPTN
5 acute closed-angle glaucoma 10.3 PEX19 OPTN
6 morgagni cataract 10.3 PHEX CRYAA
7 cataract 25 10.2 CRYGS CRYBB2
8 anisometropia 10.2 OPTN ADAMTSL4
9 presbyopia 10.2 CRYGS CRYAA
10 glaucoma 3, primary congenital, a 10.2 PAX6 OPTN CRYGS
11 juvenile glaucoma 10.2 PHEX PAX6 OPTN
12 postural orthostatic tachycardia syndrome 10.2 FBN1 ADAMTSL4
13 tricuspid valve prolapse 10.2 PHEX FBN1
14 autosomal recessive cutis laxa type iii 10.2 OPTN FBN1
15 eye accommodation disease 10.2 CRYGS CRYAA
16 mature cataract 10.2 CRYGS CRYBB2 CRYAA
17 vitreous detachment 10.2 VEGFA LAMA3
18 congenital aphakia 10.2 PAX6 OPTN FOXE3
19 blood group, globoside system 10.2 VEGFA OPTN CRYGS
20 sclerocornea 10.2 OPTN FOXE3
21 keratopathy 10.2 PAX6 FBN1 AKR1B1
22 degenerative myopia 10.2 VEGFA CRYAA
23 aniridia 1 10.1 PAX6 OPTN FOXE3
24 diabetic cataract 10.1 VEGFA GBA3 AKR1B1
25 cataract 9, multiple types 10.1 CRYBB2 CRYAA
26 uveal disease 10.1 PHEX PEX19 PAX6 OPTN
27 cataract-glaucoma 10.1 PITX3 OCRL
28 coloboma of macula 10.1 PAX6 OPTN FOXE3
29 cataract microcornea syndrome 10.1 CRYGD CRYBB2 CRYAA
30 cerulean cataract 10.1 CRYGD CRYBB2
31 anterior segment dysgenesis 2 10.1 PITX3 FOXE3
32 cataract 44 10.1 CRYBB2 CRYAA
33 iris disease 10.1 PHEX PEX19 PAX6 OPTN CRYAA
34 neovascular glaucoma 10.1 VEGFA OPTN
35 nuclear senile cataract 10.1 LAMA3 CRYGS CRYGD CRYAA
36 cataract 30, multiple types 10.1 GJA3 CRYGD CRYBB2
37 phacogenic glaucoma 10.0 PHEX PEX19 OPTN FBN1 CRYAA
38 anterior segment dysgenesis 10.0 PITX3 PAX6 FOXE3
39 conjunctival degeneration 10.0 PAX6 CRYAA
40 peters-plus syndrome 10.0 PITX3 PAX6 FOXE3
41 myopia 10.0 VEGFA PAX6 FBN1 CRYAA
42 anterior segment dysgenesis 1 10.0 PITX3 PAX6 FOXE3 CRYGS
43 microphthalmia 9.9 PITX3 PAX6 FOXE3 CRYAA
44 early-onset nuclear cataract 9.9 GJA3 CRYGD CRYBB2 CRYAB CRYAA
45 posterior polar cataract 9.9 PITX3 GJA3 CRYGD CRYAB
46 cataract 16, multiple types 9.8 PITX3 GJA3 CRYGS CRYGD CRYAB CRYAA

Graphical network of the top 20 diseases related to Lens Disease:



Diseases related to Lens Disease

Symptoms & Phenotypes for Lens Disease

UMLS symptoms related to Lens Disease:


eye manifestations

GenomeRNAi Phenotypes related to Lens Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.98 GJA3
2 Decreased viability GR00402-S-2 9.98 ADAMTSL4 AKR1B1 CRYAA CRYAB CRYBB2 CRYGD
3 no effect GR00402-S-1 9.62 ADAMTSL4 AKR1B1 CRYAA CRYAB CRYBB2 CRYGD

MGI Mouse Phenotypes related to Lens Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.5 AKR1B1 FBN1 MYH9 OCRL PAX6 PHEX
2 vision/eye MP:0005391 9.4 ADAMTSL4 AKR1B1 CRYAB CRYBB2 CRYGD CRYGS

Drugs & Therapeutics for Lens Disease

Drugs for Lens Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
2
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-63-6 5991
3
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
4
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
7
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
10
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 1 82034-46-6, 129260-79-3 9865442 444025
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
13
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
14
Ketorolac Approved Phase 4,Phase 3,Not Applicable 66635-83-4, 74103-06-3 3826
15
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 9004-61-9 53477741
16
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 1,Phase 2 56-12-2 119
17
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2 60142-96-3 3446
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
20
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 68602 5311068
21
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
22
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 32986-56-4 36294 5496
23
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
24
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
25
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
26
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
27
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
28
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
29
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
30
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
31
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
32
Levofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 100986-85-4 149096
33
Ofloxacin Approved Phase 4,Phase 3,Not Applicable 82419-36-1 4583
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35 tannic acid Approved Phase 4,Not Applicable
36
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
37 Orange Approved Phase 4
38
Azithromycin Approved Phase 4 83905-01-5 55185 447043
39
Gatifloxacin Approved, Investigational Phase 4,Phase 1,Not Applicable 112811-59-3 5379
40
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2 85721-33-1 2764
41
Bimatoprost Approved, Investigational Phase 4,Phase 2 155206-00-1 5311027
42
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
43
Enoxaparin Approved Phase 4 9005-49-6 772
44
Dalteparin Approved Phase 4 9005-49-6
45
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
46
Difluprednate Approved Phase 4,Phase 3 23674-86-4 443936
47
Fluprednisolone Approved Phase 4,Phase 3 53-34-9
48
Brinzolamide Approved Phase 4,Not Applicable 138890-62-7 68844
49
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
50 Homatropine Approved Phase 4 87-00-3

Interventional clinical trials:

(show top 50) (show all 839)
# Name Status NCT ID Phase Drugs
1 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
2 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
3 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
4 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
5 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
6 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
7 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
8 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
9 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
10 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
11 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
12 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
13 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
14 Sedation Methods During Cataract Surgery Completed NCT03054103 Phase 4 Midazolam + Ketamine 10 MG/ML: 0.5 ML;Midazolam + Ketamine 10 MG/ML: 1 ML;Midazolam + Normal saline
15 Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia Completed NCT02771912 Phase 4 Propofol;Placebo
16 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
17 Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses. Completed NCT02633228 Phase 4
18 Visual Acuity After the Combined Binocular Implantation of +2.75 Diopters and +3.25 Diopters Tecnis Multifocal Intraocular Lenses. Completed NCT02633072 Phase 4
19 Dropless vs. Standard Drops Contralateral Eye Study Completed NCT02515045 Phase 4 TriMoxiVanc;Moxifloxacin HCl 0.5%;Ilevro;Prednisolone acetate 1%
20 Visual Acuity After the Combined Binocular Implantation of +2.5 Diopters and +3.0 Diopters ReSTOR Multifocal Intraocular Lenses. Completed NCT02314572 Phase 4
21 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
22 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
23 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
24 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
25 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
26 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
27 Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500 Completed NCT01550939 Phase 4
28 Visual Outcomes After Implantation of a New Multifocal Intraocular Lens Completed NCT01505816 Phase 4
29 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
30 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
31 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
32 Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL Completed NCT01275118 Phase 4
33 Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL Completed NCT01248572 Phase 4
34 Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL) Completed NCT01210807 Phase 4
35 Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery Completed NCT01199510 Phase 4
36 Evaluation of 3 Intraocular Lenses Following Lens Extraction Completed NCT01122576 Phase 4
37 Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses Completed NCT01061918 Phase 4
38 Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses Completed NCT01061281 Phase 4
39 Spherical Aberration and Contrast Sensitivity Function in Eyes Implanted With Spherical and Aspheric Intraocular Lenses: A Clinical Trial Completed NCT01028872 Phase 4
40 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
41 Outcomes of Phacoemulsification With Torsional Ultrasound Completed NCT01010490 Phase 4
42 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
43 Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront Completed NCT00999492 Phase 4
44 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL Completed NCT00934622 Phase 4
45 Check of Optical Features and Accuracy of the Zeiss ZO Lens After Selection and Calculation With OKULIX Completed NCT00842959 Phase 4
46 Effect on Wound Healing of Vigamox Versus Cravit Completed NCT00840580 Phase 4 Moxifloxacin 0.5% ophthalmic solution (Vigamox);Levofloxacin 0.5% ophthalmic solution (Cravit)
47 Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intraocular Lens Completed NCT00838045 Phase 4
48 Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL Completed NCT00818116 Phase 4
49 Clinical Evaluation of a New Aspheric Intraocular Lens. Completed NCT00786565 Phase 4
50 Dexmedetomidine vs. Propofol for Cataract Surgery Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine

Search NIH Clinical Center for Lens Disease

Cochrane evidence based reviews: lens diseases

Genetic Tests for Lens Disease

Anatomical Context for Lens Disease

MalaCards organs/tissues related to Lens Disease:

41
Eye, Retina

Publications for Lens Disease

Articles related to Lens Disease:

# Title Authors Year
1
Diagnosis and treatment of lens diseases. ( 1458330 )
1992
2
Documentation of lens diseases. ( 511290 )
1979
3
Concomitant progressive deafness, chronic nephritis, and ocular lens disease. ( 13950238 )
1963

Variations for Lens Disease

Expression for Lens Disease

Search GEO for disease gene expression data for Lens Disease.

Pathways for Lens Disease

GO Terms for Lens Disease

Biological processes related to Lens Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 AKR1B1 CRYAA CRYAB FOXE3 VEGFA
2 protein stabilization GO:0050821 9.62 CRYAA CRYAB GBA3 PEX19
3 visual perception GO:0007601 9.55 CRYAA CRYBB2 CRYGD GJA3 PAX6
4 negative regulation of neurogenesis GO:0050768 9.54 PAX6 PITX3
5 dopaminergic neuron differentiation GO:0071542 9.52 PITX3 VEGFA
6 positive regulation of neuroblast proliferation GO:0002052 9.51 PAX6 VEGFA
7 eye photoreceptor cell development GO:0042462 9.49 PAX6 VEGFA
8 monocyte differentiation GO:0030224 9.48 MYH9 VEGFA
9 lens fiber cell differentiation GO:0070306 9.43 CRYGD PITX3
10 cornea development in camera-type eye GO:0061303 9.4 FOXE3 PAX6
11 iris morphogenesis GO:0061072 9.37 FOXE3 PAX6
12 camera-type eye development GO:0043010 9.35 CRYAB CRYBB2 FBN1 FOXE3 PAX6
13 negative regulation of intracellular transport GO:0032387 9.26 CRYAA CRYAB
14 lens development in camera-type eye GO:0002088 9.1 CRYAB CRYGD CRYGS FOXE3 PAX6 PITX3

Molecular functions related to Lens Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 CRYAA CRYAB CRYBB2 FBN1 OPTN VEGFA
2 structural constituent of eye lens GO:0005212 9.02 CRYAA CRYAB CRYBB2 CRYGD CRYGS

Sources for Lens Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....